1-2 of 2
Enzo Pavone, MD
Close
Sort by
Journal Articles

Clinical and Molecular Results of the Multicenter Randomized GITMO-IIL Trial in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Rituximab-Supplemented High-Dose Sequential Chemotherapy (R-HDS) Is Superior to CHOP-R in Molecular Remissions Rate, EFS and PFS.

Marco Ladetto, MD, Federica de Marco, MD, Fabio Benedetti, MD, Umberto Vitolo, MD, Caterina Patti, MD, Alessandro Rambaldi, MD, Anna Marina Liberati, MD, Maurizio Musso, MD, Alessandro Pulsoni, MD, Attilio Olivieri, MD, Enzo Pavone, MD, Enrico Pogliani, MD, Delia Rota Scalabrini, MD, Andrea Gallamini, MD, Vincenzo Callea, MD, Irene Ricca, MD, Mario Boccadoro, MD, Ignazio Majolino, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2006) 108 (11): 325.
https://doi.org/10.1182/blood.V108.11.325.325
Published: 2006
Journal Articles

Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.

Marco Ladetto, MD, Irene Ricca, MD, Fabio Benedetti, MD, Umberto Vitolo, MD, Caterina Patti, MD, Alessandro Rambaldi, MD, Anna Marina Liberati, MD, Maurizio Musso, MD, Alessandro Pulsoni, MD, Attilio Olivieri, MD, Enzo Pavone, MD, Enrico Pogliani, MD, Delia Rota Scalabrini, MD, Andrea Gallamini, MD, Vincenzo Callea, MD, Barbara Mantoan, PhD, Mario Boccadoro, MD, Ignazio Majolino, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Corrado Tarella, MD
Journal: Blood
Blood (2005) 106 (11): 675.
https://doi.org/10.1182/blood.V106.11.675.675
Published: 2005